Civica Launches Its First Lower-Cost Generic Drug

August 5, 2022

Civica, a nonprofit created by hospital groups to help lower generic drug prices, has launched its first product, abiraterone acetate, a prostate cancer treatment.

The company’s CivicaScript unit is now offering abiraterone acetate 250 mg tablets for use in combination with the steroid medication prednisone to treat patients with prostate cancer that has spread to other parts of the body.

This drug is available to pharmacies for $160 per bottle of 120 tablets, which typically provides a supply for one month. The average retail price is $5,422.18 before any discounts, according to GoodRx.

The newly released drug will initially be made available through the specialty pharmacy Lumicera Health Services and Intermountain Healthcare, Utah’s largest hospital system. Additional pharmacies will be added to the list as they come on board, Civica said.

View today's stories